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Abstract 
Background: Infection of cardiac implantable electronic devices is a serious cardiovascular disease and it is associ‑
ated with a high mortality. Mycobacterium species may rarely cause cardiac implantable electronic devices infection.
Case presentation: We are reporting a case of miliary tuberculosis in an Arab patient with dilated cardiomyopa‑
thy and a cardiac resynchronization therapy‑defibrillator device that was complicated with infection of his cardiac 
resynchronization therapy‑defibrillator device. To our knowledge, this is the third case in the literature with such a 
presentation and all patients died during the course of treatment. This underscores the importance of early diagnosis 
and management. We also performed a literature review of reported cases of cardiac implantable electronic devices 
infection related to Mycobacterium species.
Conclusions: Cardiac implantable electronic devices infection due to Mycobacterium species is an uncommon but a 
well‑known entity. Early diagnosis and prompt management may result in a better outcome.
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Background
Infection of cardiac implantable electronic devices 
(CIEDs) is a serious cardiovascular disease and it is asso-
ciated with a high mortality. CIEDs infection may occur 
as a pocket infection or as infection on the leads with 
infective endocarditis. Cardiac device-related infective 
endocarditis (CDR-IE) may occur as a primary infection 
of the CIED system or as a secondary infection as a result 
of hematogenous seeding during a bacteremia secondary 
to a distant infected focus [1].
Mycobacterium tuberculosis (TB) is an infection that 
primarily affects the lungs, but it can involve any other 
organs and structures such as the kidney, spine, brain, 
and rarely the heart. TB disease can be fatal if not treated 
properly (http://www.cdc.gov).
Tuberculosis endocarditis (TBE) has been reported 
for many years with involvement of native or prosthetic 
valves mostly in cases of miliary TB [2]. Mycobacterium 
species are another uncommon but well-described path-
ogen in CIED infections [3].
We are reporting a case of miliary TB in an Arab patient 
with dilated cardiomyopathy and a cardiac resynchroni-
zation therapy-defibrillator (CRT-D) device. His condi-
tion was complicated with TB meningitis and a CDR-IE 
with vegetations on the leads. He underwent surgical 
removal of the CRT-D device and leads and a gram stain 
of the vegetations was positive for acid-fast bacilli (AFB). 
We also performed a literature review of reported cases 
with Mycobacterium species related CIEDs infection.
Case presentation
A 50-year-old male Arab patient with non-ischemic 
dilated cardiomyopathy, biventricular failure with left 
ventricular ejection fraction (LVEF) of 20 %, moderate to 
severe mitral regurgitation and tricuspid regurgitation, 
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left bundle branch block, and non-sustained ventricu-
lar tachycardia. Cardiac catheterization did not show 
any significant coronary artery disease. He underwent a 
CRT-D device implantation, as he was symptomatic with 
shortness of breath, New York Heart Association Func-
tional Classification-II. He had no history of diabetes 
mellitus, hypertension, or dyslipidemia. He was on anti-
heart failure medications and was on the heart transplan-
tation list.
He presented to the Emergency Department 8 months 
after CRT-D device implantation with 2 months’ history 
of high-grade fever, chills, rigors, and weight loss. There 
was no history of concomitant respiratory, gastroenter-
ology, cardiovascular, or neurologic localizing symp-
toms. There was no history of contact with febrile or 
TB patients. He was seen at another medical center and 
started on intravenous (IV) vancomycin and gentamicin 
for possible infective endocarditis involving his CRT-D 
device leads but with no improvement.
On presentation, he was looking chronically ill but not 
in acute distress. He was febrile with a temperature of 
38.8 °C, but he was hemodynamically stable with a blood 
pressure of 107/57  mm  Hg, and heart rate of 98 beats 
per minute. Oxygen saturation was 92–94 % on room air. 
Cardiovascular exam showed a jugular venous pressure 
(JVP) at 4  cm above the sternal angle; normal first and 
second heart sounds with a soft systolic murmur at left 
lower sternal border which was reported in his previous 
physical exam. The device site in the left upper chest was 
normal. There was no lower limb edema and no stigmata 
of infective endocarditis. Chest exam showed bilateral 
basal crepitations. Neurological exam was unremarkable.
Laboratory tests; CBC showed mild anemia, and 
thrombocytopenia with normal white blood count. Renal 
profile was normal and hepatic profile showed mild ele-
vation of aspartate aminotransferase (AST) and total bili-
rubin, and low albumin. Cardiac enzymes showed mild 
elevation of Troponin T. Lactic acid was elevated. Labo-
ratory test values are summarized in Table 1. The 12 lead 
electrocardiogram showed sinus tachycardia at 106 beats 
per minute with atrial sensed and biventricular paced 
rhythm.
The chest X-ray showed a diffuse miliary shadowing 
in both lungs suggestive of tuberculosis. There was mild 
ground-glass attenuation, especially in the right para-
cardiac region. The heart was normal in size with CRT-D 
leads in place. There was no pleural effusion seen (Fig. 1).
The high-resolution computed tomography (CT) chest 
was consistent with miliary TB. There was no axillary, 
hilar or mediastinal lymphadenopathy (Fig. 2).
Based on the clinical presentation, the chest X-ray 
and CT chest findings, he was started on first-line anti-
TB therapy in the form of rifampin 600  mg orally once 
daily, ethambutol 1200  mg orally once daily, pyrazina-
mide 2000 mg orally once daily, and isoniazid (isonicoti-
nylhydrazide or INH) 300 mg orally once daily, with the 
addition of vitamin B6 25 mg orally once daily, and pred-
nisone 60 mg orally once daily.
The trans-thoracic echocardiogram showed moderately 
dilated LV with severe global hypokinesis and severely 
reduced function (LVEF <25 %).The CRT-D device leads 
were seen in the right atrium and right ventricle. There 
were no obvious masses on the leads or on any of the 
cardiac valves to suggest vegetations. There was mild to 
moderate mitral regurgitation. The right ventricular sys-
tolic pressure was elevated at 30–40  mmHg. There was 
no pericardial effusion.
The transesophageal echocardiogram was performed, 
and it showed a mass in the superior vena cava (SVC) 
around the CRT-D device leads, extending into the right 
atrium (RA). A thin flickering structure consistent with 
a remnant of a Eustachian valve or Chiari network was 
also noted. No masses were seen on them to suggest free 
Table 1 Laboratory test results on admission
CBC Complete blood count; WBC White blood cell count; Hb Hemoglobin; Hct 
Hematocrit; PLT Platelets; e‑GFR estimated Glomerular filtration rate; CK Creatine 
kinase; CO2 Carbon dioxide
Test Patient’s value Normal range
CBC
 WBC 6.11 109/L 3.90–11.00
 Hb 107 g/L 135–180
 Hct 0.311 L/L 0.370–0.520
 PLT 89 109/L 155–435
Renal profile
 Urea 5.2 mmol/L 2.5–7.5
 Creatinine 75 umol/L 64–115
 e‑GFR >60 mL/min/1.73 m2 >60
 Potassium 3.6 mmol/L 3.5–5.0
 Sodium 124 mmol/L 134–147
 Chloride 94 mmol/L 98–111
Liver function test
 ALT 15 U/L 10–45
 AST 64.2 U/L 10–45
 Albumin 25 g/L 32–48
 Total bilirubin 29 umol/L 0.0–21.0
Glucose
 Random glucose 5.60 mmol/L 2.7–18.0
Cardiac enzymes
 CK 83 U/L 24–195
 Troponin T 0.022 ug/L 0.01–0.10
Others
 CO2 18 mmol/L 22–31
 Lactic acid 3.93 mmol/L 0.9–1.8
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moving vegetations on other parts of the leads, but some 
thickening was seen on one segment of wire. It was very 
thin and could represent a fibrin/fibrous tissue deposit. No 
masses were seen on any of the four valves. A small peri-
cardial effusion was seen and “tissue” lines in the visceral 
pericardium were seen which could be fibrin, a hematoma, 
or tissue related to tuberculosis pathology (Fig. 3).
The blood cultures and urine culture were all nega-
tive. The work up was negative for HACEK group 
(Haemophilus species, Aggregatibacter species, Cardio-
bacterium hominis, Eikenella corrodens, and Kingella 
kingae), and other bacterial and viral infection including 
human immunodeficiency virus (HIV) and respiratory 
viruses.
Bronchoscopy and bronchoalveolar lavage were per-
formed, and pathology examination showed a necrotiz-
ing granulomatous inflammation and special stains for 
AFB were positive. The culture showed Mycobacterium 
tuberculosis and sensitivity came back as sensitive to all 
first line anti-TB therapy.
His clinical course was complicated by acute renal fail-
ure with an increase in serum creatinine to 351 μmol/L 
and urea to 37 mmol/L. It was felt that the cause of his 
renal impairment was due to cardio-renal syndrome. 
It improved gradually and he did not require hemodi-
alysis. He also had confusion and was noted to have a 
tonic–clonic seizure disorder. He was intubated, put on 
mechanical ventilation and started on anti-seizure treat-
ment with IV levetiracetam (keppra) and phenytoin. 
Electroencephalogram showed a severe diffuse encepha-
lopathy with periodic epileptiform discharges and con-
tinuous slow activity, generalized (delta coma). CT brain 
showed a preserved gray-white matter differentiation 
with no evidence of acute established territorial infarc-
tion, intra-axial or extra-axial hemorrhage, hydrocepha-
lus, mass effect, or midline shifting.
Lumbar puncture was performed and cerebrospi-
nal fluid (CSF) analysis showed a pale yellow, slightly 
turbid fluid with labs of: RBC 110 (normally 0), WBC 
300  ×  109/L (0–5  ×  106/L) with neutrophils 72, band 
Fig. 1 Posterior anterior and lateral chest X‑ray showing diffuse miliary shadowing in both lungs (Arrows). The cardiac resynchronization therapy‑
defibrillator device and leads in place
Fig. 2 Computed tomography (CT) chest axial plane showing diffuse 
randomly distributed ground‑glass nodules (blue arrows) involving 
bilateral lungs consistent with military tuberculosis. Implantable 
cardioverter defibrillator leads seen (yellow arrows)
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1, lymphocytes 22, and monocytes 5. Glucose was 
0.12 mmol/L (2.2–3.90 mmol/L), and protein 3580 mg/L 
(150–450  mg/L). Mycobacterium tuberculosis com-
plex DNA was positive and Mycobacterium tuberculo-
sis complex was isolated from the CSF. These findings 
were consistent with TB meningitis. Furthermore, he 
had melena with a drop in his hemoglobin to 69 g/L. He 
required transfusion of two units of packed red blood 
cells (PRBC). Upper gastroenterology endoscopy was 
performed, and it revealed a duodenal ulcer, which was 
cauterized. His thrombocytopenia continued and plate-
lets dropped further to 14 × 109/L. Hematology service 
was involved and it was felt that his thrombocytopenia 
was secondary to his TB infection. Coombs test was posi-
tive and peripheral blood smear showed no significant 
schistocytes making thrombotic thrombocytopenic pur-
pura (TTP) unlikely.
It was decided to remove his CRT-D device leads sur-
gically due to the large size of the vegetations. Once he 
was relatively stable he was taken to the operating room 
and under general anesthesia a median sternotomy was 
performed and he was put on cardiopulmonary bypass 
machine. The RA was opened and the vegetation was 
noted to extend from the SVC to mid-RA (Fig. 4).
The vegetation was removed and sent for culture and 
sensitivity. The three leads were removed completely. 
Cardiopulmonary bypass was weaned off gradually with 
no difficulty. The patient tolerated the procedure and 
was transferred to the Cardiac Surgery Intensive Care 
Unit (CSICU) on inotropic support. The microbiology 
test of the vegetation revealed 10 colonies of Mycobacte-
rium tuberculosis complex. In the CSICU, he was noted 
to have a high-grade fever and hemodynamic instability 
despite maximum inotropic support. He ultimately went 
into a multi-organ failure and died a few days later.
Discussion
We are presenting a case of miliary tuberculosis (TB) 
with infective endocarditis involving cardiac resynchro-
nization therapy device leads. We believe that this patient 
had a miliary TB that was complicated by infection of the 
CRT-D devices leads due hematogenous spread. There 
was no evidence of device pocket infection and miliary 
TB preceded the CDR-IE.
Infection of CIEDs is a serious cardiovascular disease 
which is associated with a high mortality. The incidence 
of CIEDs infection in a population-based study is 1.9 per 
1000 device-years with a higher probability of infection 
after implantable cardioverter defibrillator (ICD) com-
pared with permanent pacemaker (PPM) implantation 
[4]. The diagnosis and management of CIEDs infections 
are difficult [5].
Fig. 3 Transesophageal echocardiogram at mid esophageal level showing mass in the right atrium attached to the lead
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Local device infection is defined as an infection lim-
ited to the pocket of the cardiac device and is clinically 
suspected in the presence of local signs of inflammation 
at the generator pocket, including warm site, erythema, 
fluctuance, wound dehiscence, erosion, tenderness or 
purulent drainage [6]. CDR-IE is defined as infection 
extending to the electrode leads, cardiac valve leaflets 
or endocardial surface [1]. As stated above our patient 
clearly had a CDR-IE secondary to hematogenous spread 
of the miliary TB.
Several factors have been associated with CIED infec-
tions, which may be divided firstly into patient factors 
such as renal failure, corticosteroid use, congestive heart 
failure, hematoma formation, diabetes mellitus, antico-
agulation use, and fever within the 24  h before implan-
tation [6–11]. Secondly, procedural factors such as the 
type of intervention [12, 13], device revisions, the site of 
intervention, the number of indwelling leads, the use of 
pre-procedural temporary pacing, failure to administer 
perioperative antimicrobial prophylaxis [14], and opera-
tor experience [11] all play a role.
Our patient had a CRT-D device with three leads which 
put him at higher risk for CIED infection.
In terms of microbiological causes of CDR-IE, Staphy-
lococci especially Coagulase-Negative species (CoNS), 
accounts for 60–80  % of cases in most of the reported 
series [15, 16]. A variety of CoNS species have been 
described [6, 15]. Corynebacterium spp., Propionibacte-
rium acnes, Gram-negative bacilli and Candida spp. are 
rarely identified as pathogens in CIED infection [6, 15].
CIED infection due to Mycobacterium species is an 
uncommon but a well-recognized entity.
Review of literature showed 25 case reports of CIED 
related infections due to Mycobacterium species [17–39], 
with two different Mycobacteria species in one patient 
[20], and three cases in one report [31]. Tables  2 and 3 
show Mycobacterial infections of implanted pacemakers 
and ICDs respectively, as reported in literature. The infec-
tion was mostly pocket infection and rarely bacteremia 
with leads involvement. The infection occurred between 
8 days and 20 years from the last device related procedure. 
It occurred with both transvenous [17, 18, 20–22, 24–27, 
30, 31, 33–39] and epicardial device implantations [19, 
23, 28, 29, 32]. Mycobacterium tuberculosis was reported 
in seven cases [18, 23, 28, 31, 36] with mostly pocket 
infection. In the two cases with miliary TB, both patients 
died. The first patient died in hospital after a prolonged 
admission due to renal and respiratory failure, and recur-
rent ventricular fibrillation [18]. The second patient died 
after discharge while awaiting re-implantation of ICD 
in spite of the fact he had been equipped with a LifeVest 
[36]. The late presentation, severe systemic involvement, 
and underlying severe heart failure were key risk fac-
tors in our patient’s ultimate outcome. Mycobacterium 
fortuitum was reported in nine cases [20–22, 24, 26, 27, 
30, 38, 39] with pocket infection in five cases and pocket 
with lead or bacteremia infection in four cases. Mycobac-
terium abscessus was reported in two cases [19, 33] with 
pocket infection. Mycobacterium goodii was reported in 
two cases [25, 29] with pocket infection plus bacteremia 
in the first case. Mycobacterium avium complex [17], and 
M. avium intracellulare complex [32] in one case causing 
epicardial PM and ICD pocket infection respectively. Also 
it was reported with M. chelonae [20], M. peregrinum [34], 
and M. phlei [37]. These organisms are commonly found 
in the environment and likely contaminate the device or 
pocket at the time of insertion or during surgical manipu-
lation. Reactivation of M. tuberculosis causing a CIED 
infection has also been identified in some of these case 
reports [23, 28, 31].
The widespread use of AFB staining and mycobacterial 
cultures has undoubtedly increased diagnostic accuracy 
Fig. 4 Vegetation on the lead
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[40]. Ziehl–Neelsen staining has a sensitivity of 50–80 % 
while that of blood culture is approximately 98 % [41, 42].
Early identification of the Mycobacterium species can 
provide predictable antimicrobial susceptibility patterns. 
The best chance of cure is obtained with a combination of 
at least two active antimicrobials given for a minimum of 
4 weeks, plus removal of the CIEDs [43].
Conclusion
CIEDs infection due to Mycobacterium species is an 
uncommon but a well-known entity. Early diagnosis and 
prompt management may result in a good outcome. In 
case of suspected military TB early initiation of anti-TB 
therapy is recommended while awaiting culture results.
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